Reduced prothrombinase inhibition by tissue factor pathway inhibitor contributes to the factor V Leiden hypercoagulable state by Jeremy P. Wood, Lisa M.

Slides:



Advertisements
Similar presentations
TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain by Natalia Reglińska-Matveyev, Helena M. Andersson, Suely M. Rezende,
Advertisements

Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1 by Ilka Ott, Martin.
Factor Xa Activation of Factor V Is of Paramount Importance in Initiating the Coagulation SystemClinical Perspective by Tim J. Schuijt, Kamran Bakhtiari,
Factor XIII in plasma, but not in platelets, mediates red blood cell retention in clots and venous thrombus size in mice by Sravya Kattula, James R. Byrnes,
Activation of factor XI by products of prothrombin activation
by Kathryn Lagrue, Alex Carisey, David J
Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression by Chang-jun Hu, Frank A. Baglia, David C.B.
Polyphosphates rock! A role in thrombosis?
The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice by Hitendra Singh Chand, Xin.
Protein S Gla-domain mutations causing impaired Ca2+-induced phospholipid binding and severe functional protein S deficiency by Suely M. Rezende, David.
Volume 6, Issue 2, Pages (February 1998)
High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors by Glaivy Batsuli, Wei Deng, John.
Kinetics and mechanics of clot contraction are governed by the molecular and cellular composition of the blood by Valerie Tutwiler, Rustem I. Litvinov,
Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking by James R. Byrnes, Cédric Duval, Yiming Wang,
Recombinant factor VIIa restores aggregation of αIIbβ3-deficient platelets via tissue factor–independent fibrin generation by Ton Lisman, Jelle Adelmeijer,
by Christina K. Ullrich, Jerome E. Groopman, and Ramesh K. Ganju
Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase.
Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface by Hironao Wakabayashi, Fatbardha Varfaj,
Volume 110, Issue 8, Pages (April 2016)
Inhibition of collagen-induced platelet aggregation by anopheline antiplatelet protein, a saliva protein from a malaria vector mosquito by Shigeto Yoshida,
by Laurent O. Mosnier, Andrew J
Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk by Alisa S. Wolberg, Dougald.
Alterations in platelet secretion differentially affect thrombosis and hemostasis by Smita Joshi, Meenakshi Banerjee, Jinchao Zhang, Akhil Kesaraju, Irina.
by Robert F. Kelley, Canio J. Refino, Mark P
The γ-carboxyglutamic acid domain of anticoagulant protein S is involved in activated protein C cofactor activity, independently of phospholipid binding.
by Herbert Bosshart, and Ruth F. Jarrett
by Fabian Stavenuiter, and Laurent O. Mosnier
by Cornelis van 't Veer, Neal J. Golden, and Kenneth G. Mann
by Matthew F. Whelihan, Vicentios Zachary, Thomas Orfeo, and Kenneth G
Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of.
Apoptotic Vascular Endothelial Cells Become Procoagulant
by Andrew J. Gale, Mary J. Heeb, and John H. Griffin
C1qTNF–related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen by Gerald.
Cobalt hematoporphyrin inhibits CLEC-2–podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice by Nagaharu Tsukiji, Makoto Osada,
Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity by Gary E. Gilbert, Valerie A. Novakovic,
by Jue Wang, Usha R. Pendurthi, and L. Vijaya Mohan Rao
A phosphatidylserine binding site in factor Va C1 domain regulates both assembly and activity of the prothrombinase complex by Rinku Majumder, Mary Ann.
Mechanism of factor VIIa–dependent coagulation in hemophilia blood
Volume 10, Issue 9, Pages (September 2003)
Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells by Uri Rozovski, Ji Yuan Wu, David.
Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis by Manasa K. Nayak, Nirav Dhanesha,
by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka
The absence of ADCC by nivolumab in vitro.
A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant by Shauna L. French, Claudia Thalmann, Paul F.
Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin by Romy M. W. Kremers, Stéphane Zuily, Hilde Kelchtermans,
Cell-derived vesicles exposing coagulant tissue factor in saliva
ICAM-1–targeted thrombomodulin mitigates tissue factor–driven inflammatory thrombosis in a human endothelialized microfluidic model by Colin F. Greineder,
by Sondra Downey-Kopyscinski, Ellen W
Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors by Manu T. Kalathottukaren, A.
by Changjie Zhang, Anju Kelkar, and Sriram Neelamegham
Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency by Gillian N. Gidley, Lori A. Holle,
Naturally Occurring Inhibitors
Volume 19, Issue 7, Pages (July 2012)
P. reichenowi CIDR domains inhibit the APC-EPCR interaction.
Platelet HMGB1 is required for efficient bacterial clearance in intra-abdominal bacterial sepsis in mice by Hui Zhou, Meihong Deng, Yingjie Liu, Chenxuan.
by Ludovic Durrieu, Alamelu Bharadwaj, and David M. Waisman
Soluble GPVI is elevated in injured patients: shedding is mediated by fibrin activation of GPVI by Samantha J. Montague, Céline Delierneux, Christelle.
Characterization of the activity of RBCs bound by hTM-scFv fusions and their therapeutic efficacy in a microfluidic model of inflammatory thrombosis. Characterization.
Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency by Michelle M. Castillo, Qiuhui.
by Defne Bayik, Debra Tross, Lydia A
Growth factor release from LP-PRP system preparations.
by Kelly E. Johnson, Julia R. Ceglowski, Harvey G. Roweth, Jodi A
Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera by Richard B. Pouw, Mieke C. Brouwer,
Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies by Nadine Müller-Calleja, Svenja.
Positive and Negative Control of Enhancer-Promoter Interactions by Other DNA Loops Generates Specificity and Tunability  Nan Hao, Keith E. Shearwin, Ian.
by Sarah M. Nordstrom, Brian A. Holliday, Brandon C. Sos, James W
Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its action by Shiva Keshava, Jagan Sundaram,
by Fabian C. Verbij, Nicoletta Sorvillo, Paul H. P
Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S by José A. Fernández, Xiao Xu, Ranjeet K.
Empty basement membrane sleeves and endothelial sprouts.
Presentation transcript:

Reduced prothrombinase inhibition by tissue factor pathway inhibitor contributes to the factor V Leiden hypercoagulable state by Jeremy P. Wood, Lisa M. Baumann Kreuziger, Paul E. R. Ellery, Susan A. Maroney, and Alan E. Mast BloodAdv Volume 1(6):386-395 February 14, 2017 © 2017 by The American Society of Hematology

Jeremy P. Wood et al. Blood Adv 2017;1:386-395 © 2017 by The American Society of Hematology

The threshold for TF- and FXa-initiated thrombin generation is lower in FVL plasma than in FV plasma and is dependent on TFPI. (A) A total of 0.05 to 1 pM TF or (B) 5 to 100 pM FXa initiated thrombin generation in plasma anticoagulated with citrate and CTI containing FV (black) or FVL (gray). The threshold for TF- and FXa-initiated thrombin generation is lower in FVL plasma than in FV plasma and is dependent on TFPI. (A) A total of 0.05 to 1 pM TF or (B) 5 to 100 pM FXa initiated thrombin generation in plasma anticoagulated with citrate and CTI containing FV (black) or FVL (gray). Reactions were started by the addition of CaCl2 to plasma containing 4 μM PC:PE:PS in the presence (dashed line) or absence (solid line) of anti-K2 antibody (50 nM). At 0.05 pM TF or 5 pM FXa, no thrombin generation occurred unless TFPI activity was blocked. TF experiments were performed using 2 each of FV and FVL donors. FXa experiments were performed with 10 donors of each genotype. Representative thrombin generation curves from a single FV donor and a single FVL donor are shown (A-B). Jeremy P. Wood et al. Blood Adv 2017;1:386-395 © 2017 by The American Society of Hematology

Inhibition of plasma TFPI reduces the lag time for initiation of thrombin generation to a greater extent in FV plasma than in FVL plasma. Inhibition of plasma TFPI reduces the lag time for initiation of thrombin generation to a greater extent in FV plasma than in FVL plasma. Plasma thrombin generation assays were initiated with either (A-B) 100 pM, (C) 20 pM, or (D-F) also 100 pM FXa. Assays were performed in the absence or presence of (A) 1 nM TFPIα, (B-C) 50 nM anti-K2, (D) 50 nM anti-K3C, (E) 50 nM anti-K1, or (F) 1 μM LIKTKRKRKK. Shown are the changes in lag time, relative to the untreated plasma control (n = 10 for each genotype). The boxes represent the 25th to 75th percentile; the whiskers represent minimum and maximum values; and the lines represent the median values. Het, heterozygous. Jeremy P. Wood et al. Blood Adv 2017;1:386-395 © 2017 by The American Society of Hematology

FVL reduces the TFPI-dependent activation threshold for FXa-initiated thrombin generation in PRP. Thrombin generation was initiated in PRP, containing FV (black) or FVL (gray), with 5 to 100 pM FXa and 20 μg/mL collagen, in the absence (lines) or presence (dashes) of 50 nM anti-K2. FVL reduces the TFPI-dependent activation threshold for FXa-initiated thrombin generation in PRP. Thrombin generation was initiated in PRP, containing FV (black) or FVL (gray), with 5 to 100 pM FXa and 20 μg/mL collagen, in the absence (lines) or presence (dashes) of 50 nM anti-K2. Experiments were performed using 5 each of FV and FVL donors. Shown are representative thrombin generation curves from a single FV donor and a single FVL donor. Jeremy P. Wood et al. Blood Adv 2017;1:386-395 © 2017 by The American Society of Hematology

FVL reduces the TFPI-dependent activation threshold for FXa-initiated fibrin formation. FVL reduces the TFPI-dependent activation threshold for FXa-initiated fibrin formation. Fibrin formation was initiated in FV plasma (red) or FVL plasma (blue) by the addition of (A) 5 pM or (B) 0.5 pM FXa, 4 μM PC:PE:PS, and 5 mM CaCl2, and monitored at 405 nm. Experiments were performed in the absence (solid lines) or presence of anti-K2 (long dashed lines) or anti-K3C (short dashed line). Experiments were performed using 8 each of FV and FVL donors. Shown are representative fibrin formation curves from a single FV donor and a single FVL donor. OD, optical density. Jeremy P. Wood et al. Blood Adv 2017;1:386-395 © 2017 by The American Society of Hematology

Prothrombinase containing FVL is less susceptible to inhibition by TFPIα. Prothrombinase containing FVL is less susceptible to inhibition by TFPIα. Various amounts of (A) TFPIα or (B) LIKTKRKRKK were incubated with 0.5 nM FV810 (□) or FVL810 (●), 20 μM PC:PE:PS, and 3 μM DAPA. Reactions were initiated with mixtures of 1.4 μM prothrombin and 5 nM FXa. The prothrombinase activity ± SD is reported as percent of control from 3 sets of experiments. Jeremy P. Wood et al. Blood Adv 2017;1:386-395 © 2017 by The American Society of Hematology

A small change in inhibitory kinetics may explain the thrombosis associated with combined FVL and TFPIα haploinsufficiency. A small change in inhibitory kinetics may explain the thrombosis associated with combined FVL and TFPIα haploinsufficiency. TFPIα inhibition of prothrombinase containing FXa-FVa (red) is reproduced from Wood et al.10 TFPIα inhibition of prothrombinase containing FXa-activated FVL (blue) is extrapolated, assuming a 1.7-fold increase in IC50. With FV, 50% inhibition is achieved by 0.9 nM TFPIα (i; green dashed line). This same concentration of TFPIα would be expected to inhibit ∼30% of prothrombinase containing FVL (ii; purple dashed line), and a 50% reduction in TFPIα would result in ∼10% prothrombinase inhibition (iii; orange dashed line). Jeremy P. Wood et al. Blood Adv 2017;1:386-395 © 2017 by The American Society of Hematology